Novartis AG agreed to pay more than $729 million to settle U.S. government charges that the company paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said.
Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.
A look at how the California Consumer Privacy Act put into effect in 2020 will impact the pharmaceutical industry.
Sanofi reached a civil settlement with the U.S. Securities and Exchange Commission fully resolving the SEC’s investigation into possible violations of the U.S. Foreign Corrupt Practices Act.
A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.
The U.S. FDA issued a warning letter to Imprimis Pharmaceuticals Inc. accusing it of making false or misleading claims that its compounded eye medications had the agency’s approval.